<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OPRELVEKIN</span><br/>(o-prel've-kin)<br/><span class="topboxtradename">Neumega<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">hematopoietic growth factor</span><br/><b>Prototype: </b>Epoetin Alfa<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Hematopoietic growth factor (interleukin-11) that is produced by recombinant DNA.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by return of postnadir platelet count toward normal (<img src="../images/special/greaterorequal.gif"/>50,000). Increases
         platelet count in a dose-dependent manner.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention of severe thrombocytopenia following myelosuppressive chemotherapy (not effective after myeloablative chemotherapy).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to oprelvekin; myeloablative chemotherapy; myeloid malignancies; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with left ventricular dysfunction, cardiac disease, CHF, history of atrial arrhythmias, or other arrhythmias; electrolyte
         imbalance, hypokalemia; respiratory disease; papilledema; thromboembolic disorders; older adults; cerebrovascular disease,
         stroke, TIAs; pleural effusion, pericardial effusion, ascites; increased intracranial pressure, brain tumor, visual disturbances;
         hepatic or renal dysfunction; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Thrombocytopenia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 50 mcg/kg once daily starting 624 h after completing chemotherapy and continuing until platelet count is <img src="../images/special/greaterorequal.gif"/>50,000
               cells/mcL or up to 21 d<br/><span class="rdage">Child:</span> <span class="rdroute">SC</span> <i>8 mo17 y,</i> 75100 mcg/kg once daily starting 624 h after completing chemotherapy and continuing until platelet count is <img src="../images/special/greaterorequal.gif"/>50,000 cells/mcL or up to 21 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li> 				Note: Do not use if solution is discolored or if it contains particulate matter. 			</li>
</ul><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Reconstitute solution by gently injecting 1 mL of sterile water for injection (without preservative) toward the sides of the
            vial. Keep needle in vial and gently swirl to dissolve but do not shake solution. Without removing needle, withdraw specified
            amount of oprelvekin for injection.
         </li>
<li>Give as single dose into the abdomen, thigh, hip, or upper arm.</li>
<li>Discard any unused portion of the vial. It contains no preservatives.</li>
<li>Use reconstituted solution within 3 h; store at 2°8° C (36°46° F) until used.</li>
<li>Store unopened vials at 2°8° C (36°46° F). Do not freeze.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Edema, neutropenic fever, fever,</span> asthenia, pain, chills, myalgia, bone pain, dehydration. <span class="typehead">CNS:</span> <span class="speceff-common">Headache, dizziness, insomnia,</span> nervousness. <span class="typehead">CV:</span> <span class="speceff-common">Tachycardia,</span> vasodilation, palpitations, syncope, atrial fibrillation/flutter, peripheral edema, capillary leak syndrome.  <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, mucositis, diarrhea,</span> oral moniliasis, anorexia, constipation, dyspepsia. <span class="typehead">Hematologic:</span> Ecchymosis. <span class="typehead">Respiratory:</span> <span class="speceff-common">Dyspnea, rhinitis, cough, pharyngitis,</span> pleural effusion, pulmonary edema, exacerbation of preexisting pleural effusion.  <span class="typehead">Skin:</span> Alopecia, <span class="speceff-common">rash,</span> skin discoloration, exfoliative dermatitis. <span class="typehead">Special Senses:</span> Conjunctival injection, amblyopia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 80% absorbed from SC injection site. <span class="typehead">Onset:</span> Days 59. <span class="typehead">Duration:</span> 7 d after last dose. <span class="typehead">Distribution:</span> Distributes to highly perfused organs. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 6.9 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor platelet counts until adequate recovery; periodically monitor CBC with differential and serum electrolytes.</li>
<li>Monitor carefully for and immediately report S&amp;S of fluid overload, hypokalemia, and cardiac arrhythmias.</li>
<li>Monitor persons with preexisting fluid retention carefully (e.g., CHF, pleural effusion, ascites) for worsening of symptoms.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Review patient information leaflet with special attention to administration directions.</li>
<li>Report any of the following to the physician: Shortness of breath, edema of arms and/or legs, chest pain, unusual fatigue
            or weakness, irregular heartbeat, blurred vision.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>